Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C5H13NO7P2.2Na |
| Molecular Weight | 307.0863 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[Na+].CN(C)CCC(O)(P(O)([O-])=O)P(O)([O-])=O
InChI
InChIKey=JFGHPLSPUGOSLV-UHFFFAOYSA-L
InChI=1S/C5H15NO7P2.2Na/c1-6(2)4-3-5(7,14(8,9)10)15(11,12)13;;/h7H,3-4H2,1-2H3,(H2,8,9,10)(H2,11,12,13);;/q;2*+1/p-2
| Molecular Formula | Na |
| Molecular Weight | 22.98976928 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C5H13NO7P2 |
| Molecular Weight | 261.1067 |
| Charge | -2 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Olpadronate, a nitrogenated bisphosphonate that can inhibit bone resorption. Although it shares the therapeutic and pharmacological properties of pamidronate and alendronate, it has a greater dosage amplitude, more predictable effects, and greater digestive tolerability than other bisphosphates. Clinical trials have shown that the oral olpadronate was well tolerated and effective in the treatment of Paget's disease. In addition, the drug is ongoing in phase II clinical trials in the Netherlands. This clinical trial has to assess the efficacy of the intravenous drug in decreasing the average back pain intensity from baseline.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Interventions for Improving Bone Mineral Density and Reducing Fracture Risk in Osteogenesis Imperfecta: A Mixed Treatment Comparison Network Meta-analysis of Randomized Controlled Clinical Trials. | 2018 |
|
| Bisphosphonates for Paget's disease of bone in adults. | 2017-12-01 |
|
| [Treatment of Paget's disease with olpadronate. Its efficacy in partial responders to oral pamidronate]. | 1997 |
Sample Use Guides
Paget's disease: olpadronate was given orally in doses of 100 to 200 mg/day. Initial dose and/or increment of the dose during treatment were decided accordingly to the biochemical response
Olpadronate intra venous in chronic low back pain: 20 mg and 40 mg
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:56:37 GMT 2025
by
admin
on
Mon Mar 31 18:56:37 GMT 2025
|
| Record UNII |
G90M9V9GMQ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID30153250
Created by
admin on Mon Mar 31 18:56:37 GMT 2025 , Edited by admin on Mon Mar 31 18:56:37 GMT 2025
|
PRIMARY | |||
|
121368-58-9
Created by
admin on Mon Mar 31 18:56:37 GMT 2025 , Edited by admin on Mon Mar 31 18:56:37 GMT 2025
|
PRIMARY | |||
|
G90M9V9GMQ
Created by
admin on Mon Mar 31 18:56:37 GMT 2025 , Edited by admin on Mon Mar 31 18:56:37 GMT 2025
|
PRIMARY | |||
|
198715
Created by
admin on Mon Mar 31 18:56:37 GMT 2025 , Edited by admin on Mon Mar 31 18:56:37 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
